ICI are monoclonal antibodies that target these immune-inhibitory molecules, expressed by T-cells, such as CTLA-4 and PD-1, as well as the PD-1 ligand expressed by tumor cells but also epithelial cells and others in physiological conditions, resulting in enhanced immunity and often autoimmunity (38). This evidence concerns the gene CTLA4 and neoplasm.